H. LEE MOFFITT CANCER CENTER AN

H. Lee Moffitt Cancer Center specializes in advanced oncological research and the development of innovative cancer treatment modalities. Their core capabilities encompass a broad spectrum of biomedical research, including the engineering of augmented tumor-infiltrating lymphocytes, the repurposing of pharmaceutical modulators for mutant-specific treatments, and the development of AI-powered noninvasive biomarker testing. The organization demonstrates deep technical expertise in immunotherapy, neuro-oncology, and the study of tumor microenvironments, specifically regarding meningeal stroma in melanoma. Additionally, they implement comprehensive patient care interventions, ranging from telehealth-enabled patient navigation for rural populations to nutritional and exercise programs designed to prevent cancer progression. The contractor works exclusively with the Department of Health, primarily through the Florida Cancer Innovation Fund and the Bankhead Coley Cancer Research Program. Their relationship with the agency is centered on executing high-level research grants and pilot programs aimed at accelerating cancer treatment and improving survivor outcomes through clinical trials and biomedical exploration. The organization is vertically specialized in the oncology and biomedical research sectors. Their market positioning is that of a premier research institution focused on translational medicine, integrating laboratory discovery with clinical application across various cancer types, including breast, prostate, and colorectal cancers. Based in Tampa, Florida, the entity operates as a specialized healthcare and research provider. There are no government certifications listed in the provided record.